2001
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectiveness
1998
Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS
Freedberg K, Paltiel A. Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS. PharmacoEconomics 1998, 14: 165-173. PMID: 10186457, DOI: 10.2165/00019053-199814020-00005.Peer-Reviewed Original ResearchConceptsHIV patient careOpportunistic infectionsInfection preventionPatient careImmune system destructionSpecific opportunistic infectionsMajor opportunistic infectionNew antiretroviral therapiesQuality of lifeCost-effectiveness evaluationCost-effectiveness analysisCost effectivenessProphylaxis regimensAntiretroviral therapyHIV diseaseHIV infectionViral loadClinical guidelinesConsiderable financial strainProphylaxisClinical advancesViral replicationEffective agentInfectionHIV